Successful resolution of refractory chronic cough induced by gastroesophageal reflux with treatment of baclofen
© Xu et al.; licensee BioMed Central Ltd. 2012
Received: 7 April 2012
Accepted: 1 October 2012
Published: 18 October 2012
Gastroesophageal reflux induced cough is a common cause of chronic cough, and proton pump inhibitors are a standard therapy. However, the patients unresponsive to the standard therapy are difficult to treat and remain a challenge to doctors. Here, we summarized the experience of successful resolution of refractory chronic cough due to gastroesophageal reflux with baclofen in three patients. It is concluded that baclofen may be a viable option for gastroesophageal reflux induced cough unresponsive to proton pump inhibitor therapy.
Gastroesophageal reflux induced cough (GERC) is a common cause of chronic cough and accounts for 5-41% of chronic cough.  Although proton pump inhibitors are a standard therapy for GERC, some patients do not respond to the antireflux medical treatment and remain a challenge to doctors. Here, we report three patients with GERC resistant to proton pump inhibitors but successfully treated with baclofen.
Clinical characteristics of the patients
Cough duration (month)
Cough symptom score
Cough threshold to capsaicin
The results of multi-channel intraluminal impedance combined with pH monitoring in the patients
SAP for acid reflux (%)
SAP for nonacid reflux (%)
Acidic reflux (n)
Weakly acidic reflux (n)
Weakly alkaline reflux (n)
Gas reflux (n)
Liquid reflux (n)
Mixed reflux (n)
Proximal extent (n)
Bolus exposure (%)
Bolus clearance (s)
A 63-year-old housewife with a 2-year history of dry cough was referred for the suspicious GERC. She described that cough occurred through day and night, and disturbed her sleep, with the occasional heartburn, regurgitation and urinary incontinence (Table 1). The triggers included the cold and smoky air. A past medical history of hypertension and diabetes was present, but angiotensin-converting enzyme inhibitors were not currently being taken. On physical examination, only the follicular hyperplasia was found on the posterior pharyngeal mucosa. Her chest radiographs and lung function testing were normal, bronchial provocation with histamine did not demonstrate the existence of airway hyperresponsiveness. Cell differentials in the induced sputum consisted of 60.5% of monocytes, 37.0% of lymphocytes, 2.0% of neutrophils and 0.5% of eosinophils. MII-pH showed a serious abnormal acid reflux and positive symptom association probability for acid reflux (Table 2). When waiting for the results of the laboratory investigations, the patients was treated with antihistamine/ decongestant for a week, but without success.
A 42 year-old man with a 2-year history of persistent dry cough was referred for the diagnosis of cause. He coughed all the day, severely at postprandial time or when going to bed. An occasional regurgitation was described but without heartburn or the sensation of postnasal drip (Table 1). The patient was a lifetime nonsmoker, and had no history of chronic rhinitis or occupational exposure to pollutants. Six months ago, he visited to another respiratory clinic, where chest X-ray and lung function examinations were within the normal limits, and bronchial challenge confirmed airway hyperresponsiveness, as shown by 3.0 μmol of the cumulative provocative dose of histamine causing a 20% fall in FEV1. Then, the diagnosis of cough variant asthma was considered. However, the anti-asthma therapy including the initial inhalation of salmeterol/fluticasone 50/250μg, twice a day for one month and the subsequent trials with oral prednisone and montelukast failed to relieve the cough.
Physical examination was normal. The repeated bronchial provocation with histamine demonstrated the recovery of airway responsiveness. Cell examination in the induced sputum showed 82.5% of macrophages,12.0% of lymphocytes and 5.5% of neutrophils. MII-pH study was performed which revealed a slight abnormal acid reflux and the marginal level of symptom association probability (Table 2).
In the patients with presumptive GERC whose cough persists despite proton pump inhibitors therapy, three possibilities arise to explain the continuing cough: 1. the gastric acid may be incompletely suppressed, and the patients are having continuing acid reflux that causes cough by microaspiration or esophageal-tracheobronchial reflex . 2. non-acid (weakly acidic or alkaline) reflux is producing cough. It is proposed that cough due to non-acid reflux is resistant to proton pump inhibitors since they only reduce the pH of the refluxate but not the amount and the rate of reflux episodes . 3. the ongoing cough is not related to any continuing reflux. It has been reported that only 40.8% of the patients with the positive findings of 24 hour esophageal pH monitoring were responsive to the high dose of omeprazole . In all the three patients, MII-pH uncovered the abnormal acid or nonacid reflux and the temporal association between reflux and cough. Therefore, GERC could be established since the other common causes of chronic cough such as upper airway cough syndrome, cough variant asthma and eosinophilic bronchitis were excluded with the previous investigation procedure and specific therapies. The diagnosis of GERC was finally confirmed by the favorable response to the subsequent antireflux treatment containing omeprazole and baclofen even though the initial standard antiacid medical treatment failed.
In theory, the therapeutic options available for refractory GERC resistant to proton pump inhibitors include prokinetic agents, transient lower esophageal sphincter relaxation inhibitors and antireflux surgery because they all have the ability to reduce the frequency of reflux and volume of refluxate. At present, the efficacy of prokinetic agents has not been ascertained, which can explain the failure of the initial antireflux therapy containing domperidone. Antireflux surgery should not be the preferred choice when a cause and effect relationship between reflux and chronic cough is not definitely established. We selected baclofen, a potent inhibitor of transient lower esophageal sphincter relaxation, as an add-on trial for GERC unresponsive to proton pump inhibitors since it has been proposed in the management of difficult to treat gastroesophageal reflux disesase . To our knowledge, this is the first report for the successful resolution of refractory GERC with baclofen.
Baclofen modulates the transient lower esophageal sphincter relaxations mediated by vagal reflex pathways through the activation of gamma-aminobutyric acid B receptor. Considering transient lower esophageal sphincter relaxations account for the vast majority of reflux events , it is predictable that baclofen may be helpful for refractory GERC by the inhibition of both acid and nonacid reflux. The limited studies have shown that it decreased the frequency of transient lower esophageal sphincter relaxations by 40-60% and acid or non-acid reflux episodes by 43% [6–8]. Vela has illustrated that baclofen reduced the symptoms related to acid reflux by 72% and related non-acid reflux by 21% in a small cohort of patients with heartburn . In addition, baclofen has also been recognized for a long time to have a nonspecific antitussive activity both in animals  and in humans [11, 12]. There have been several lines of evidence illustrating baclofen can treat the cough caused by angiotensin-converting enzyme inhibitors  and refractory chronic cough with unknown cause . Our observations revealed that 2–4 week course of baclofen was needed for the significant alleviation of cough, and the complete resolution was generally achieved in the 2–3 months. Because MII-pH is an invasive procedure, our patients refused to undergo a repeated examination after the cough was resolved. Therefore, we were unable to directly evaluate the inhibitory efficacy of baclofen on acid or non-acid reflux in the patients. Nevertheless, it can be speculated that baclofen may play a therapeutic role through the effective blockade of all types of reflux events as well as the nonspecific antitussive effect.
A variety of central nervous system-related side effects can be produced by Baclofen, including somnolence, dizziness, fatigue, weakness and trembling. The other adverse reactions consist of dry mouth, nausea, vomiting, diarrhea or constipation. These side effects usually occur in the early or high-dose phase of treatment, and often limit the utility of baclofen in clinical practice . In our patients, there was only slight dizziness and sleepiness in patient 2 and 3 respectively, which did not interrupt the treatment of baclofen. The lack of obvious side effects may be attributed to the well tolerance of the patients to the drug.
In conclusion, baclofen may be a viable option for refractory cough due to gastroesophageal reflux. Further study is needed to validate its therapeutic efficacy for GERC in the future.
Written informed consent was obtained from the patient for publication of this report and any accompanying images.
- Irwin RS: Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest. 2006, 129: 80S-94S. 10.1378/chest.129.1_suppl.80S.View ArticlePubMedGoogle Scholar
- Boeckxstaens GE, Smout A: Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2010, 32: 334-343. 10.1111/j.1365-2036.2010.04358.x.View ArticlePubMedGoogle Scholar
- Patterson RN, Johnston BT, MacMahon J, Heaney LG, McGarvey LP: Oesophageal pH monitoring is of limited value in the diagnosis of "reflux-cough". Eur Respir J. 2004, 24: 724-727. 10.1183/09031936.04.00007404.View ArticlePubMedGoogle Scholar
- Tsoukali E, Sifrim D: The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled?. J Neurogastroenterol Motil. 2010, 16: 258-264. 10.5056/jnm.2010.16.3.258.PubMed CentralView ArticlePubMedGoogle Scholar
- Boeckxstaens GE: Reflux inhibitors: a new approach for GERD?. Curr Opin Pharmacol. 2008, 8: 685-689. 10.1016/j.coph.2008.08.005.View ArticlePubMedGoogle Scholar
- Beaumont H, Boeckxstaens GE: Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy?. Am J Gastroenterol. 2009, 104: 1764-1771. 10.1038/ajg.2009.247.View ArticlePubMedGoogle Scholar
- Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH: Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut. 2002, 50: 19-24. 10.1136/gut.50.1.19.PubMed CentralView ArticlePubMedGoogle Scholar
- Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH: Control of transient lower esophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in normal subjects. Gastroenterology. 2000, 118: 7-13. 10.1016/S0016-5085(00)70408-2.View ArticlePubMedGoogle Scholar
- Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid post-prandial gastroesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther. 2003, 17: 243-251. 10.1046/j.1365-2036.2003.01394.x.View ArticlePubMedGoogle Scholar
- Bolser DC, Aziz SM, DeGennaro FC, Kreutner W, Egan RW, Siegel MI, Chapman RW: Antitussive effects of GABAB agonists in the cat and guinea-pig. Br J Pharmacol. 1993, 110: 491-495. 10.1111/j.1476-5381.1993.tb13837.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Dicpinigaitis PV, Dobkin JB: Antitussive effect of the GABA-agonist baclofen. Chest. 1997, 111: 996-999. 10.1378/chest.111.4.996.View ArticlePubMedGoogle Scholar
- Dicpinigaitis PV, Dobkin JB, Rauf K, Aldrich TK: Inhibition of capsaicin-induced cough by the gamma-aminobutyric acid agonist baclofen. J Clin Pharmacol. 1998, 38: 364-367.View ArticlePubMedGoogle Scholar
- Dicpinigaitis PV: Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors. Ann Pharmacother. 1996, 30: 1242-1245.PubMedGoogle Scholar
- Dicpinigaitis PV, Rauf K: Treatment of chronic, refractory cough with baclofen. Respiration. 1998, 65: 86-88. 10.1159/000029232.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.